(Press-News.org) CHICAGO— Cell therapy may present an option for patients with ischemic heart disease to use their own bone marrow cells to repair the damaged areas of their hearts, and may pave the way for future treatment options, according to the FOCUS trial, which will be presented as a late-breaking clinical trial March 24 at the 61st annual American College of Cardiology (ACC) scientific session.
This is the largest study to date to look at stem cell therapy, using a patient's own stem cells, to repair damaged areas of the heart in patients with chronic ischemic heart disease and left ventricular dysfunction. Researchers found that left ventricular ejection fraction (the percentage of blood leaving the heart's main pumping chamber) increased by a small but significant amount (2.7 percent) in patients who received stem cell therapy. The study also revealed that the improvement in ejection fraction correlated with the number of progenitor cells (CD34+ and CD133+) in the bone marrow; and this information will help in evaluating and designing future therapies and trials.
"FOCUS is an incredibly important trial, as it has informed the cell therapy community how to better treat this high-risk patient population, and allows us to enter into an exciting, next generation of stem cell therapy armed with more data," said study investigator Timothy D. Henry, MD, an interventional cardiologist at the Minneapolis Heart Institute® (MHI) at Abbott Northwestern Hospital in Minneapolis and director of research with the Minneapolis Heart Institute Foundation.
This multicenter study was conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), which is supported through a research grant from the National Institutes of Health's National, Heart, Lung and Blood Institute (NHLBI), with the goal to evaluate novel stem cell-based treatment strategies for individuals with cardiovascular disease.
FOCUS will be presented at ACC.12 by its lead investigator Emerson C. Perin, MD, PhD, director of clinical research for cardiovascular medicine at the Texas Heart Institute, one of the five sites in the CCTRN. The Minneapolis Heart Institute is another site of the five in the network, and a large number of CCTRN patients were enrolled in Minnesota.
For this study, which took place between April 2009 and April 2011, the five sites randomly selected 92 patients to receive stem cell treatment or placebo. The symptomatic patients, with an average age 63, all had chronic ischemic heart disease and an ejection fraction of less than 45 percent (baseline 34 percent) along with heart failure and/or angina and were no longer candidates for revascularization. "These patients had no other options, as medical management failed to improve their symptoms," explained the study's co-investigator Jay Traverse, MD, an interventionalist cardiologist at the Minneapolis Heart Institute at Abbott Northwestern Hospital and physician researcher with the Minneapolis Heart Institute Foundation.
Bone marrow was aspirated from the patients and processed to obtain just the mononuclear fraction of the marrow. In patients randomly selected to receive stem cell therapy, physicians inserted a catheter into the heart's left ventricle to inject 100 million stem cells in more than 15 sites that showed damage on the electromechanical mapping image of the heart.
"Studies such as these are able to be completed much faster because of the team approach of the network" said Sonia I. Skarlatos, PhD, NHBLI's deputy director of the division of cardiovascular sciences and program director of CCTRN.
The FOCUS trial was designed to determine whether left ventricular end systolic volume and myocardial oxygen consumption improved in patients who received stem cell treatment. Researchers also wanted to see if nuclear scans of the heart showed a reversible change in perfusion defects in patients who had received the treatment.
While the study did not achieve its primary endpoint, the researchers found that those patients with more progenitor cell types had much better improvement with ejection fraction, explained Henry, and demonstrated a linear relationship between the number of CD34+ cells and the improvement in ejection fraction.
"As a result, these findings are revealing the importance of certain cell types that are delivered and that modifying the cells may create more robust cells capable of achieving better results in future studies," concluded Traverse.
###
The study will be simultaneously published in the Journal of the American Medical Association.
Minneapolis Heart Institute Foundation
The Minneapolis Heart Institute Foundation is dedicated to creating a world without heart disease through groundbreaking clinical research and innovative education programs. MHIF's mission is to promote and improve cardiovascular health, quality of life and longevity for all.
Minneapolis Heart Institute®
The Minneapolis Heart Institute® is recognized internationally as one of the world's leading providers of heart and vascular care. This state-of-the-art facility combines the finest in personalized patient care with sophisticated technology in a unique, family-oriented environment. The Institute's programs, a number of which are conducted in conjunction with Abbott Northwestern Hospital, address the full range of heart and vascular health needs: prevention, diagnosis, treatment and rehabilitation.
Cell therapy using patient's own bone marrow may present option for heart disease
2012-03-26
ELSE PRESS RELEASES FROM THIS DATE:
Tears during coronary angioplasty: Where are they and how do they affect patient outcomes?
2012-03-26
CHICAGO – Researchers from Thomas Jefferson University Hospital discovered that blockages in the right coronary artery and those in bending areas of the coronary artery are the most common places for dissection, a tear in the artery that can occur during balloon angioplasty of the coronary arteries.
They will present their findings at the American College of Cardiology annual meeting in Chicago on Saturday, March 24 at 9 AM.
A 'controlled tear' is the mechanism by which angioplasty dilates the blocked vessels. A large tear, or spiral dissection, that continues ...
Popcorn: the snack with even higher antioxidant levels than fruits and vegetables
2012-03-26
SAN DIEGO, March 25, 2012 — Popcorn's reputation as a snack food that's actually good for health popped up a few notches today as scientists reported that it contains more of the healthful antioxidant substances called "polyphenols" than fruits and vegetables. They spoke at the 243rd National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society, being held here this week.
Joe Vinson, Ph.D., a pioneer in analyzing healthful components in chocolate, nuts and other common foods, explained that the polyphenols are more concentrated ...
Some scum! Microbe in pond scum enlisted in new cancer test
2012-03-26
SAN DIEGO, March 25, 2012 — Scientists are enlisting the living, self-propelled microbes found in pond scum — the pea-green surface slicks that form on ponds — in the development of a long-awaited new test to detect the cells that spread cancer through the bloodstream from the original tumor to new sites in the body.
In a report here today at the 243rd National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society, they described how the test is intended to not only identify the spreading of cells, but allow lab analysis of ...
Preserving arson evidence with triclosan
2012-03-26
SAN DIEGO, March 25, 2012 — A preservative in toothpastes, hand soaps, underarm deodorants and other everyday products is getting a second life, helping crime scene investigators preserve evidence of arson, scientists reported here today at the 243rd National Meeting & Exposition of the American Chemical Society (ACS).
The preservative, triclosan, would be the first evidence preservative for traces of gasoline and other ignitable fluids, or flame "accelerants," commonly used in arson, according to John V. Goodpaster, Ph.D., an international expert who reported on evidence ...
Nuclear power plants can produce hydrogen to fuel the 'hydrogen economy'
2012-03-26
SAN DIEGO, March 25, 2012 — The long-sought technology for enabling the fabled "hydrogen economy" — an era based on hydrogen fuel that replaces gasoline, diesel and other fossil fuels, easing concerns about foreign oil and air pollution — has been available for decades and could begin commercial production of hydrogen in this decade, a scientist reported here today.
Speaking at the 243rd National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society, Ibrahim Khamis, Ph.D., described how heat from existing nuclear plants could ...
J. Craig Venter, Ph.D., describes biofuels, vaccines and foods from made-to-order microbes
2012-03-26
SAN DIEGO, March 25, 2012 —Just as aspiring authors often read hundreds of books before starting their own, scientists are using decades of knowledge garnered from sequencing or "reading" the genetic codes of thousands of living things to now start writing new volumes in the library of life. J. Craig Venter, Ph.D., one of the most renowned of those scientists, described the construction of the first synthetic cell and many new applications of this work today at the 243rd National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific ...
'Noodle gels' or 'spaghetti highways' could become tools of regenerative medicine
2012-03-26
SAN DIEGO, March 25, 2012 — Medicine's recipe for keeping older people active and functioning in their homes and workplaces — and healing younger people injured in catastrophic accidents — may include "noodle gels" and other lab-made invisible filaments that resemble uncooked spaghetti with nanoscale dimensions, a scientist said here today at the 243rd National Meeting & Exposition of the American Chemical Society (ACS). The world's largest scientific society, ACS is meeting here this week with reports on more than 11,000 reports on new advances in science on its schedule.
Samuel ...
American Chemical Society President unveils initiatives for 2012
2012-03-26
SAN DIEGO, March 25, 2012 — Bassam Z. Shakhashiri, Ph.D., president of the American Chemical Society (ACS) — the world's largest scientific society — today described initiatives on climate science, the education of future scientists and commemoration of a landmark federal law that engendered some of the nation's greatest universities. Those initiatives will be the theme of Shakhashiri's presidential year.
A chemistry professor who holds the William T. Evjue Distinguished Chair for the Wisconsin Idea at the University of Wisconsin-Madison, Shakhashiri discussed the projects ...
Materials inspired by Mother Nature: A 1-pound boat that could float 1,000 pounds
2012-03-26
SAN DIEGO, March 25, 2012 — Combining the secrets that enable water striders to walk on water and give wood its lightness and great strength has yielded an amazing new material so buoyant that, in everyday terms, a boat made from 1 pound of the substance could carry five kitchen refrigerators, about 1,000 pounds.
One of the lightest solid substances in the world, which is also sustainable, it was among the topics of a symposium here today at the 243rd National Meeting & Exposition of the American Chemical Society, the world's largest scientific society. The symposium ...
Interventional radiology: Potential breakthrough to treat men's enlarged prostate
2012-03-26
A new interventional radiology treatment, prostatic artery embolization, may bring hope to men with debilitating symptoms caused by an enlarged prostate, say the group of researchers who pioneered its use. The findings were presented at the Society of Interventional Radiology's 37th Annual Scientific Meeting in San Francisco, Calif.
"Having an enlarged prostate is very common in many men over the age of 50, and these new findings provide hope for those who might not be candidates for transurethral resection of the prostate, or TURP—and may allow them to avoid serious ...